Bioness lands $15M debt facility from Horizon to fund neurorehab growth
What's the deal? Horizon Technology Finance CorporationDealroom has a profile for this one. Try Dealroom → has provided a $15 million senior credit facility to Bioness MedicalDealroom has a profile for this one. Try Dealroom →, with $10 million funded at closing and up to $5 million more available. Horizon, an affiliate of Monroe CapitalDealroom has a profile for this one. Try Dealroom →, announced the debt financing in September 2026.
What does BionessDealroom has a profile for this one. Try Dealroom → do? The company develops and commercialises FDA-approved neurorehabilitation technologies for people recovering from stroke, spinal cord injury, and other neurological conditions. Its products span functional electrical stimulation, robotic gait training, and neuromodulation, used across hospital, outpatient, and home-based care.
What's the endgame? Bioness, backed by Accelmed PartnersDealroom has a profile for this one. Try Dealroom →, plans to use the capital to expand its product portfolio and reach more patients and providers globally. "This facility provides additional capital and flexibility as we continue investing in innovation," said co-founder and chief executive officer Todd Cushman.
Why Horizon? The lender focuses on secured loans to venture- and private equity-backed companies in technology, life sciences, and healthcare. "Bioness is representative of the high-quality businesses we seek to support," said Paul Seitz, Horizon's chief investment officer.
The signal: At $15 million, the facility sits in the lower tier of disclosed rounds — roughly the 30th percentile by size. That reflects the nature of venture debt: rather than diluting equity, established companies with proven products increasingly turn to structured lending to fund growth.
Read more: wallstreet-online.de
Image credit: Generated with Gemini
